SciBase Holding AB SCIB

SciBase Holding AB (publ) ("SciBase" or the "Company") today, on 1 October 2026, announces the outcome of the rights issue of shares of approximately SEK 57.5 million resolved by the Board of Directors on 3 September 2026 pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026 (the "Rights Issue"). The subscription period ended on 29 September 2026. The outcome shows that 2,681,085 shares, corresponding to approximately SEK 40.2 million or approximately 69.9 percent of

SciBase Holding AB (publ) ("SciBase" or the "Company") announces that Bergs Securities AB ("Bergs Securities") has today, on 25 September 2026, fulfilled the letter of intent to provide a guarantee commitment (the "Guarantee Intention") announced by SciBase on 3 September 2026 in connection with the Company's ongoing rights issue of shares of approximately SEK 57.5 million (the "Rights Issue"). The fulfilment of the Guarantee Intention means that Bergs Securities has provided a binding guarantee

SciBase Holding AB (publ) ("SciBase" or the "Company") today announces that the Company has resolved to update the first day of trading in subscription rights and paid subscribed shares ("BTA") on Nasdaq First North Growth Market in the Company's ongoing rights issue of shares (the "Rights Issue"). According to the preliminary timetable, the first day of trading in subscription rights and BTAs was to be 15 September 2026. Under the updated timetable, the first day of trading in subscription righ

The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") is publishing an information document in connection with the rights issue of shares of approximately SEK 58 million (the "Rights Issue"), which the Company's Board of Directors resolved upon on 3 September 2026. The information document is available on the Company's website and will also be available on Bergs Securities AB's ("Bergs Securities") website at https://www.bergssecurities.se/.

SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5.

The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general meeting held on 19 May 2026, resolved to carry out an issue of shares of approximately SEK 57.5 million, before deduction of transaction costs, with preferential rights for the Company's shareholders (the "Rights Issue"). All existing shareholders will receive one (1) subscription right for each share held on the record date of 10 September 2026.

SciBase Holding AB ("SciBase") (STO: SCIB) a leader in AI-based devices for detection and prevention in dermatology, today announced that Pia Renaudin has decided to leave her role as CEO at SciBase. Pia Renaudin has, after almost 3 years as CEO of SciBase Holding AB (publ), informed the Board of her decision to leave the company. She will be taking on a new CEO role elsewhere. Pia Renaudin will remain in her position until the 31st of December 2026.

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced the publication of a study in the peer-reviewed journal Allergy demonstrating that results from Nevisense measurements obtained shortly after birth identified children who subsequentially developed atopic dermatitis (AD).

SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that the board of directors has resolved on the record date for the reverse share split. At the Annual General Meeting of SciBase Holding AB (publ) ("SciBase" or the "Company") on 19 May 2026, it was resolved on a reverse share split of the Company's shares, whereby one hundred (100) existing shares shall be consolidated into one (1) share (Sw. sammanläggning 1:10

SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to show that surfactants in household cleaning products disrupt the human skin barrier.